Carvedilol’s advantage in cirrhosis gets real-world confirmation

Clinical takeaway: Current guidelines favor carvedilol for patients with compensated cirrhosis and clinically significant portal hypertension who require a nonselective beta-blocker. These real-world comparative data bolster that recommendation, with carvedilol initiation associated with lower six-month risks of major hepatic decompensation, including variceal hemorrhage and ascites-related complications, than nadolol or propranolol.

Nonselective beta-blockers reduce portal pressure and help prevent variceal bleeding and other complications of portal hypertension. Although recent guidance has increasingly favored carvedilol, direct comparative evidence versus nadolol and propranolol has been limited.

A new retrospective cohort study found that carvedilol initiation was associated with meaningfully lower six-month rates of major decompensation events compared with nadolol or propranolol among US adults with cirrhosis.

Hepatic decompensation—including ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy, and variceal hemorrhage—is associated with substantially worse prognosis, more frequent hospitalization, and increased mortality, making prevention a major treatment goal.

Researchers analyzed insurance claims data from 26,128 adults with cirrhosis who initiated carvedilol, nadolol, or propranolol between 2013 and 2025. Compared with nadolol, carvedilol was associated with a 20% lower relative risk of major decompensation events at six months. Compared with propranolol, carvedilol was associated with a 17% lower relative risk.

The benefit signal included clinically familiar complications. Carvedilol was associated with lower risk of variceal hemorrhage and lower risk of ascites, spontaneous bacterial peritonitis, or hepatorenal syndrome compared with either nadolol or propranolol.

Carvedilol's additional α1-blocking activity produces greater portal pressure reduction but also greater blood pressure lowering than traditional nonselective beta-blockers. Careful dose titration and monitoring remain important, particularly in patients with hypotension, advanced decompensation, renal dysfunction, or limited circulatory reserve.

“Among US patients with cirrhosis, carvedilol initiation—as opposed to nadolol or propranolol—was associated with meaningfully lower rates of major decompensation events,” the study authors concluded.

Source: Simon TG, et al. (2026 July 7) Ann Intern Med. The comparative effectiveness of carvedilol versus other nonselective β-blockers in cirrhosis